We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




CtDNA Forecasts Non-Metastatic Colorectal Cancer Recurrence

By LabMedica International staff writers
Posted on 29 May 2019
Print article
Image: A histopathology of colorectal carcinoma: an example of moderately differentiated adenocarcinoma showing complicated glandular structures in a desmoplastic stroma (Photo courtesy of the David Geffen School of Medicine at the University of California).
Image: A histopathology of colorectal carcinoma: an example of moderately differentiated adenocarcinoma showing complicated glandular structures in a desmoplastic stroma (Photo courtesy of the David Geffen School of Medicine at the University of California).
Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine). Most colorectal cancers are due to old age and lifestyle factors, with only a small number of cases due to underlying genetic disorders.

Colorectal cancer diagnosis is performed by sampling of areas of the colon suspicious for possible tumor development, typically during colonoscopy or sigmoidoscopy, depending on the location of the lesion. It is confirmed by microscopical examination of a tissue sample. In Europe the five-year survival rate for colorectal cancer is less than 60% and in the developed world about a third of people who get the disease die from it.

An international team of scientists led by those at the Johns Hopkins University School of Medicine (Baltimore, MD, USA) included in a study 58 patients with stage I, II, or III CRC who underwent radical surgical resection at four Swedish hospitals from February 2, 2007, to May 8, 2013. Blood samples were collected at one month after the surgical procedure and every 3 to 6 months thereafter for circulating tumor DNA (ctDNA) analysis. Patients were followed up until metachronous metastases were detected, or for a median of 49 months. Data analysis was performed from March 1, 2009, to June 23, 2018.

While most of the patients did not have detectable levels of ctDNA in their blood after surgery, their search for known patient tumor mutations, using the Safe-SeqS assay, identified more than a dozen patients who were positive for ctDNA. The team found that disease recurrence and relapse occurred in all but three of the 13 early-stage CRC patients with post-surgical ctDNA, pointing to the potential benefit of ongoing testing for ctDNA after surgical tumor resection. On average, the ctDNA turned up in relapsing patients some three months before clinicians could see the recurrent disease by radiologic screening or clinical symptoms. The team did not see disease recurrence over an average of more than four years of follow up in the 45 remaining, ctDNA-free CRC patients.

Louise Olsson, MD, PhD, a corresponding author of the study, said, “Serial circulating tumor DNA levels during post-operative surveillance can be used as a triage test to stratify patients with resected colorectal cancer on the basis of their risk of recurrence.” The study was published on May 9, 2019, in the journal JAMA Oncology.

Related Links:
Johns Hopkins University School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.